Bladder cancer treatment is undergoing a significant transformation, marked by advances in diagnostics, novel therapies, and evolving treatment strategies. Innovations such as liquid biomarkers and MRI are enhancing diagnostic precision, while new drug classes are expanding options for non-muscle invasive bladder cancer (NMIBC) and metastatic disease.
This event will provide a comprehensive overview of these groundbreaking changes and their implications for clinical practice.
By attending this meeting, you will:
- Gain insight into newly developed therapies for NMIBC and their potential to redefine oncological practice
- Build your understanding on the current advancements and anticipated future developments in bladder cancer diagnostics, including the use of both liquid and imaging biomarkers
- Explore evolving therapeutic strategies across the spectrum of bladder cancer, including metastatic disease, perioperative treatment, and bladder preservation in MIBC
This event offers a unique opportunity to engage with leading experts in urologic oncology, explore the latest evidence-based advances, and prepare for the next chapter in bladder cancer care.
Interested in applying to the Sylvia Lawler Prizes 2025, which will be awarded during the event to the winning presenter?
Sylvia Lawler Prize 2025 - Scientific
Submission deadline: Sunday 22 June 2025
Open to: All clinicians in training
Prize: £250 to winning presenter
Apply here
Sylvia Lawler Prize 2025 - Clinical
Submission deadline: Sunday 22 June 2025
Open to: All clinicians in training
Prize: £250 to winning presenter
Apply here
Follow us on:
Facebook
Instagram
LinkedIn
Twitter
YouTube
We would like to thank our sponsor Merck for their financial support of this meeting.
Please note that the main scientific programme and content has not been influenced in any way by the sponsors.